Local Cecal Cancer - Optimization of Surgical Treatment

Recruiting now · Not applicable

Conditions studied: Colonic Neoplasms Malignant, Cecal Neoplasms

In brief

The purpose of this study is to determine the clinical efficacy, safety, and oncologic outcomes of ileocecal resection (ICR) with D3 lymphadenectomy compared to standard right hemicolectomy(RHC) for cecal cancer.

Key facts

Study ID

NCT06121089

Run by

Moscow Clinical Scientific Center

People needed

200

Starts

2022-09-01

Expected to finish

2027-01-01

Last updated by the study team

2023-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age.
• ECOG status 0-2.
• Histologically confirmed adenocarcinoma of the colon.
• Clinical stage T1-3; N+; M0.
• The physical status from ASA classification I, II, III or IV.
• Written informed consent.

You may not qualify if…

• Synchronous or metachronous malignancy.
• Locally-advanced tumor (T>3).
• Presence of distant metastases (M1).
• Complicated tumor: obstruction, perforation.
• Neoadjuvant chemotherapy.
• Medical contraindications for surgical treatment.
• Pregnancy or breast feeding.
• Medical or psychiatric conditions that compromise the patient's ability to give informed consent or comply with the study protocol.

Where it is running

• Moscow Clinical Scientific Center — Moscow, Russia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.